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| INTRODUCTION
Intensity-modulated radiation therapy (IMRT) treatment for prostate cancer has gained in popularity over the last two decades. Compared to three-dimensional conformal radiation therapy (3DCRT), IMRT has been proven to maintain the same level of tumor control probability (TCP) while decreasing normal tissue toxicity. One important advantage of the IMRT technique is the ability to shape dose distributions, thus avoiding nearby critical structures such as bladder and rectum. [1] [2] [3] Due to the high cumulative dose levels typically delivered to the prostate, and its proximity to sensitive normal structures, it is important to accurately locate the IMRT-shaped dose distribution. Imageguided radiation therapy (IGRT) has evolved as a valuable tool in achieving an accurate placement of such shaped, high dose level distributions. There are several prostate IGRT techniques widely used for prostate treatments, including implanted fiducial markers, ultrasound, cone-beam CT, and Calypso four-dimensional (4D) localization system. The prostate treatment margins could be reduced due to IGRT technique. [4] [5] [6] Calypso is a prostate target positioning technique which can be used to directly localize and track prostate position during external beam radiation therapy with a precision of about 0.5 mm. 7 Traditionally, prostate margins have been 1 cm for 3DCRT, and were subsequently reduced to 5 mm with the introduction of IGRT.
The possibility of further reducing margins is the subject of several current investigations. [11] [12] [13] In this study we calculate composite dose delivered to the prostate by using the Calypso tracking-data-stream acquired during each of the 42 fractions of seven prostate patients treated in our clinic (294 total fractions). We then evaluate the composite distributions that would have been delivered under multiple simulated Calypso tolerance level schemes and to recommend a tolerance level strategy that is based on achievable delivered dose distribution.
| MATERIALS AND METHODS
For the purposes of this study, a total of seven Calypso-localized prostate cancer patients treated in our clinic were randomly selected for retrospective analysis with IRB approval. Each patient was pre- Additionally, we endeavored to explore the dosimetric implications of utilizing either the 3 mm tolerance scheme or the 5 mm tolerance scheme. For each of these tolerance schemes we explored the worst case scenario by assuming that on each given day of the 42 fraction Calypso-guided treatment course the prostate position was located at one of the eight extreme corners of the 3 or 5 mm "box" defined by the respective tolerance scheme (e.g., x = +3, y = +3, z = +3; x = −3, y = +3, z = +3; x = −3, y = −3, z = +3; and so on for all eight "corners"). By uniformly distributing the prostate positional error between the eight possible worst case locations, we developed a composite plan that was representative of a reasonable "worst case" delivered dose distribution for each tolerance scenario, for both the 3 and 5 mm PTV margin plans, for each patient.
To characterize plan quality under each of the studied scenarios, we recorded the maximum, mean, and minimum doses for prostate, PTV, bladder, and rectum. The volumetric coverage of prostate, PTV, bladder, and rectum for 100% and 95% prescription dose (71.82 Gy)
were calculated, along with the volume coverage of bladder and rectum for 65 and 40 Gy two dose levels. The reason for choosing 65 and 40 Gy dose levels for volume coverage of bladder and rectum is that these two dose levels are reasonably used for normal tissue tolerance analysis of prostate treatment plan.
| RESULTS AND DISCUSSIONS

3.A | Composite dose calculation
The averaged location of the prostate (while the treatment beam was on of that day) was calculated from the Calypso system's continuous tempero-positional data stream.The values of x, y, and z were in the range of 0 to 3 mm, since the Calypso tolerance level was set to 3 mm and any excursion above that limit led to the patient being repositioned. Composite dose calculations based on Calypso tracking data of 42 fractions for both 5 and 3 mm PTV margins were very similar to original plan for all patients. The difference in maximum, mean, and minimum doses for prostate, PTV, bladder, and rectum were all <2.0% of prescription dose (Figs. 2 and 3) , with the exception of the difference of minimum dose to the PTV which was within 4.0%. The volumetric coverage difference for the prostate, PTV, bladder, and rectum for 100% and 95% prescription dose was less than 2.5%, as was the volumetric coverage of bladder and rectum at the 65 and 40 Gy levels. This essentially confirms that, when using a sophisticated, intrafractional tracking system to accurately maintain target position, an accurate delivered dose distribution can be achieved.
3.B | 3 and 5 mm Tolerance Scheme -worst case dose calculation
The difference between the original calculated treatment plan and the worst-case delivered dose scenarios is shown in Figs. 4 and 5
and Tables 1 and 2 for each tolerance scheme for all patients, for both 5 and 3 mm PTV margin plans. Doses are reported as percentage of prescribed dose and as percentage volume covered by the specified dose levels, respectively.
As seen in Figs. 4 and 5, for both 5 and 3 mm PTV margin, for both 3 and 5 mm tolerance levels, the maximum and mean prostate dose difference from original plan was within 2%, and the maximum and mean dose difference for both bladder and rectum was ranged from +1.7% to −12%, thus indicating acceptable isodose distribution for both tolerance scenarios. The only exception was for the, Tolerance Scheme, where minimum prostate dose could be as low as 77.6%. Of course, this assumes that the target is always at an extreme location within the tolerance "box." Table 1 shows the worst case combination volumetric coverage difference (from original plan) of prostate for 100% (75.6 Gy) and 95% prescription dose (71.82 Gy) for 5 and 3 mm PTV margin with combination of both 5 and 3 mm Tolerance Scheme. We can see from Table 1 that, with 5 mm PTV margin for both 5 and 3 mm Tolerance Scheme, the difference of volumetric coverage of prostate for 100% and 95% prescription dose was within 3.17%. With 3 mm PTV margin for 3 mm Tolerance Scheme, the difference of volumetric coverage of prostate was within 1.24%. We can also see from Table 1 that, even for the worst case scenario studied here, the only case in which prostate coverage is greatly compromised is for the combination of 3 mm PTV margin with 5 mm Tolerance Scheme (6.47% to 11.66% difference from the original plan). Table 2 shows bladder and rectum volumetric coverage comparison of original and worst case combination composite plans for 5 and 3 mm Tolerance Scheme, for both 5 and 3 mm PTV margins, at the dose level of 65 and 40 Gy. We can see from Table 2 , that most OAR volumetric doses at the two selected levels are reduced, relative to the original plan, for all PTV/ Worst-Case-ToleranceScheme combinations simulated here. This seems reasonable when we recall that the "Worst Case" scenarios simulated here assumed the prostate to move equally between the extreme corners of the respective Tolerance geometric "box" being explored, thus serving to "wash out" or "blur" the dose distribution of extreme OAR dose values.
The decision to only investigate the vendor recommended 3 and 5 mm tolerances instead of smaller values was made for two reasons. Firstly, even for the worst case scenario where the prostate was at the extreme of 3 mm in all directions, the dosimetric evaluation still showed that the ensuing dose distribution was within 2% of the planned distribution. While a smaller tolerance for positioning within Calypso would ensure a higher fidelity of the delivered dose distribution to the planned distribution, this would also cause for many more treatment interruptions due to the prostate moving out of these smaller margins. That would likely cause extended treatment times which would, in turn, lead to a higher likelihood of motion. 16, 17 With the 3 mm tolerances showing an adequate compromise between dose fidelity and treatment length, this was the lower limit used.
| CONCLUSION
A clinically realistic calculation of delivered composite dose can be calculated using the averaged x, y, and z target position temporal data stream provided by Calypso. Calculated composite dose distributions show that, for the patients studied here, the vast majority of dosimetric metrics agreed quite well with predicted dose (i.e., within 2%), thus confirming the dosimetric value of during treatment target tracking.
A study of the dosimetric ramifications of two different treatment interruption Tolerance Schemes (3 and 5 mm), under simulated "worst case" situations, showed that the only combination that resulted in significant/detrimental deviation from planned dose was for the, perhaps ill-advised, combination of 3 mm PTV margin with 5 mm Tolerance Scheme. Otherwise, the 3 mm Tolerance
Scheme strategy that we are currently employing appears reasonable, as does a 5 mm Tolerance Scheme scenario.
It shows that further reducing prostate margin to 3 mm is possible for Calypso tolerance level set up at 3 mm.
T A B L E 1 Target volumetric coverage comparison of original and composite plans for 5 and 3 mm Tolerance Scheme, for both 5 and 3 mm PTV margins for all seven patients. The composite plans are the sum of the eight worst case combinations of Calypso tolerance shifts of 3 and 5 mm, respectively. The values are reported as the percentage volume covered by the specified dose levels. Red and blue represents the % number was out of 10% and 5%.
